Serum levels of vascular endothelial growth factor in preeclamptic and normotensive pregnancy

Hypertension

Volumn 36, Issue 6, 2000, Pages 965-969

  Hunter, Alyson ^a   Aitkenhead, Mark ^a   Caldwell, Carolyn ^a   McCracken, Geoffrey ^a   Wilson, David ^a   McClure, Neil ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Endothelium; PE; Radioimmunoassay; Serum; Vascular endothelial growth factor

Indexed keywords

CYTOKINE; VASCULOTROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; MATERNAL HYPERTENSION; PATHOPHYSIOLOGY; PREECLAMPSIA; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PUERPERIUM;

EID: 0033669976     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.36.6.965     Document Type: Article

References (23)

1. Why mothers die
2. Placental bed spiral arteries in the hypertensive disorders of pregnancy
3. Preeclampsia is associated with a serum factor cytotoxic to human endothelial cells
4. Preeclampsia: An endothelial cell disorder
5. The biology of vascular endothelial growth factor
6. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo
7. VEGF via VEGF receptor-1 (Flt-1) mimics preeclamptic plasma in inhibiting uterine blood vessel relaxation in pregnancy: Implications in the pathogenesis of PE
8. Elevated serum levels of VEGF in patients with PE
9. Maternal plasma levels of vascular endothelial growth factor in normotensive pregnancies and in pregnancies complicated by PE
10. Vascular endothelial growth factor is increased in patients with PE
11. Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and PE
12. Variation in detection of VEGF in maternal serum by immunoassay and the possible influence of binding proteins
13. Maternal serum VEGF during early pregnancy
14. A longitudinal study of maternal serum vascular endothelial growth factor in early pregnancy
15. Evidence for the existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth factor receptor, Flt-1
16. Inhibition of vascular endothelial growth factor activity by an endogenously encoded soluble receptor
17. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation
18. Heparin in the treatment of toxemia of pregnancy
19. Hypoxia alters early human cytotrophoblasts differentiation/invasion in-vitro and models the placental defects that occur in PE
20. An ultra-structural study of utero-placental spiral arteries in hypertensive and normotensive pregnancy and fetal growth retardation
21. VEGF mRNA levels in placentae from pregnancies complicated by PE
22. Maternal serum inhibin A can predict PE
23. Total plasma fibronectin as a marker of pregnancy-induced hypertensive disorders: A longitudinal study